This is a pivotal moment for the food industry. Noting that 12% of the US population has tried the drugs, with 6% actively using them, Harold Schmitz at VC firm The March Group said the Ozempic era is helping to rejuvenate the foodtech space, which is now very much alive. Courtney McHugh, chief commercial officer at Amplifye, a UC Davis spinout with an enzyme that helps the body digest protein more effectively, added: Theres an entire secondary market that can come from any breakthrough technology. This is only the first generation of GLP-1 drugs and therefore the first generation of secondary markets, observed McHugh, who said GLP-1 drugs are driving interest in products that solve for energy levels, nutrient deficiencies, and gut issues. They are also prompting renewed interest in protein quality as well as quantity, she claimed
Mochi Health has quickly become one of the most talked-about GLP-1 providers in the telehealth space, and for good reason
BB: I mean, could you imagine like I am, Ive lost 18 pounds, Im having to get IV fluids, I cant keep down anything, and then Im told that its in my head
Double-check, then triple-check your calculations for concentration
Oversight: The Compounding Dilemma A central tension in the battle between compounding pharmacies and Big Pharma lies in the trade-off between access and safety is: access versus safety
In addition, both TTP and gAgAP downregulated transcription levels of angiotensin II receptor type 1 ( agtr1 ) and miR-132/-212, with TTP producing a comparable reduction in agtr1 to captopril and a significant decrease in miR-132/-212 expression
.jpg)
